V

Vaxcyte

Develops broad-spectrum vaccines for bacterial infections

Vice President - U.S. Market Access & Pricing

Growth & MarketingConfirmed live in the last 24 hours
Full-time

About the Job

Requirements

  • A bachelor's degree is required; an advanced degree (MBA, MPH, PharmD, or PhD) is preferred.
  • At least 15 years of experience in market access, pricing, reimbursement, or related functions within biotech or pharma.
  • Demonstrated experience supporting or leading product launches, ideally in vaccines, infectious disease, or buy-and-bill products.
  • Strong understanding of adult vaccine access dynamics, including public health recommendations, Medicare Part B and Part D reimbursement, Medicaid, 340B program implications, CDC contract vehicles (Section 317 and VFC), and site-of-care economics.
  • Experience operating in lean or pre-commercial biotech environments, with a demonstrated track record of building market access capabilities from the ground up.
  • Ability to balance strategic thinking with hands-on execution.
  • Strong cross-functional leadership and stakeholder influence skills.
  • Experience managing gross-to-net financial modelling, including rebate strategy across payers.
  • Demonstrated ability to work collaboratively with HEOR teams to translate cost-effectiveness models, budget impact analyses, and payer value dossiers into P&T committee submissions or ICER reviews.
  • Prior engagement with CDC immunization programs, state immunization programs, or ACIP-adjacent policy processes; understanding of how ACIP recommendation language drives uptake across channels.

Responsibilities

  • Lead development and execution of the U.S. market access strategy for the adult pneumococcal vaccine, including pricing, reimbursement, contracting, and channel strategy.
  • Define and drive launch readiness plans aligned to regulatory approval and immunization guideline milestones, such as ACIP or other recommending-body milestones.
  • Shape access strategies across commercial payers, Medicare, Medicaid, and public health channels.
  • Develop and execute engagement strategies for key stakeholders, including GPOs, IDNs, retail pharmacy, and public health entities.
  • Establish pricing strategy and gross-to-net assumptions, ensuring alignment with vaccine-specific market dynamics.
  • Ensure readiness for coding, coverage, reimbursement, and provider economics within buy-and-bill and pharmacy settings.
  • Partner with Medical Affairs to define and deliver HEOR and value evidence to support payer and policy decision-making.
  • Serve as the market access lead across cross-functional teams, aligning with Commercial, Medical, Regulatory, Government Affairs, and Finance.
  • Build and lead a lean market access function, leveraging external partners to scale capabilities efficiently.
  • Work cross-functionally to prepare for CDC immunization program, state immunization program, and ACIP-adjacent policy stakeholder engagements; translate ACIP recommendation language into access and coverage implications across all channels.
  • Develop and execute integrated PBM, commercial payer, and Medicare Part B and Part D contracting strategies to ensure optimal formulary positioning, coverage, and patient access across channels.
  • Support development of national retail pharmacy and alternate vaccination site strategies, establishing partnerships that maximize vaccine availability, administration, and uptake.
  • Develop scenario-based access, reimbursement, and customer adoption strategies aligned to potential ACIP recommendation outcomes and evolving adult immunization guidelines.

About the Company

Vaxcyte

Develops broad-spectrum vaccines for bacterial infections

Vaxcyte develops vaccines to prevent bacterial infections, focusing on broad-spectrum pneumococcal vaccines and other targets like Group A Strep, periodontitis, and Shigella. Its lead product, VAX-24, covers 24 Streptococcus pneumoniae strains and is produced using the XpressCF cell-free protein synthesis platform, which enables multi-strain conjugate vaccines. The company differentiates itself by combining cell-free manufacturing with broad strain coverage and has FDA Breakthrough Therapy designation for VAX-24, helping speed development. Its goal is to bring broadly protective bacterial vaccines to market, reduce serious infections worldwide, and expand its portfolio with products like VAX-31 and additional preclinical candidates.

Company size
501-1,000
Company stage
IPO
Headquarters
San Carlos, CA
Founded
2013

Recently Posted Jobs

Explore more opportunities at Vaxcyte

See more jobs